You are here

FDA Announces Recall of Valsartan-containing Products

An impurity has been found to be carcinogenic.

An impurity called N-nitrosodimethylamine (NDMA) was found in several of products containing valsartan, which is used to treat heart failure and high blood pressure. But not all products containing valsartan are being recalled. And the FDA said that because valsartan is used to treat serious medical condition, patients should keep on taking the recalled products until they have a replacement.

Based on some laboratory tests, researchers have determined that NDMA could cause cancer. “The presence of NDMA was unexpected and is thought to be related to changes in the way the active substance was manufactured,” the FDA said in a press release.

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs
Acasti reports disappointing results for a second Omega-3-based drug